Hina Jolin
About
Hina Jolin is a scholar working on Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Oncology.
According to data from OpenAlex, Hina Jolin has authored 18 papers receiving a total of 145 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 8 papers in Pathology and Forensic Medicine and 6 papers in Oncology. Recurrent topics in Hina Jolin's work include Lymphoma Diagnosis and Treatment (8 papers), Lung Cancer Treatments and Mutations (7 papers) and Mast cells and histamine (6 papers). Hina Jolin is often cited by papers focused on Lymphoma Diagnosis and Treatment (8 papers), Lung Cancer Treatments and Mutations (7 papers) and Mast cells and histamine (6 papers). Hina Jolin collaborates with scholars based in United States, United Kingdom and Canada. Hina Jolin's co-authors include Kellene A. Isom, Jon Silverman, Keenan Fenton, Andrew Grigg, Kerry J. Savage, Tracy I. George, Rachael Liu, Andrea Gallamini, John Radford and Stephen M. Ansell and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.
In The Last Decade
Hina Jolin
18 papers receiving 142 citations
Peers
Hina Jolin
A. E. Heufelder Germany
Penko Shotekov Bulgaria
Erika Pigatto Italy
Maria Stelmachowska‐Banaś Poland
Sayaka Toki Japan
Zoltán Szűcs United Kingdom
Jérôme Meunier France
Eva Nóvoa Switzerland
Javier Oesterheld United States
Eetu Heervä Finland
Citations per year, relative to Hina Jolin Hina Jolin (= 1×)
peers
A. E. Heufelder
Countries citing papers authored by Hina Jolin
Since
Specialization
Citations
This map shows the geographic impact of Hina Jolin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hina Jolin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hina Jolin more than expected).
Fields of papers citing papers by Hina Jolin
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Hina Jolin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hina Jolin. The network helps show where Hina Jolin may publish in the future.
Co-authorship network of co-authors of Hina Jolin
This figure shows the co-authorship network connecting the top 25 collaborators of Hina Jolin. A scholar is included among the top collaborators of Hina Jolin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hina Jolin. Hina Jolin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Bose, Prithviraj, Stephen T. Oh, Brian D. Modena, et al.. (2023). Initial Results from Summit: An Ongoing, 3-Part, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of Bezuclastinib in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM). Blood. 142(Supplement 1). 77–77.
2.
Vachhani, Pankit, Tsewang Tashi, Gary J. Schiller, et al.. (2023). Safety and Efficacy of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM): Results from Part 1 of the Phase 2 Apex Trial. Blood. 142(Supplement 1). 4567–4567.
3.
DeAngelo, Daniel J., Vinod Pullarkat, Miguel Piris‐Villaespesa, et al.. (2022). Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Adults with Advanced Systemic Mastocytosis (AdvSM). Blood. 140(Supplement 1). 1512–1513.
4.
Akin, Cem, Frank Siebenhaar, Michael W. Deininger, et al.. (2022). Summit: A 3-Part, Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM). Blood. 140(Supplement 1). 6838–6839.
5.
Evens, Andrew M., Joseph M. Connors, Anas Younes, et al.. (2021). Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study. Haematologica. 107(5). 1086–1094.
6.
Hutchings, Martin, John Radford, Stephen M. Ansell, et al.. (2021). Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced‐stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high‐risk patients from the ECHELON‐1 study. Hematological Oncology. 39(2). 185–195.
7.
Gotlib, Jason, Tracy I. George, Michael W. Deininger, et al.. (2021). A Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Advanced Systemic Mastocytosis (AdvSM). Blood. 138(Supplement 1). 3636–3636.
8.
Siebenhaar, Frank, Jason Gotlib, Michael W. Deininger, et al.. (2021). A 3-Part, Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM). Blood. 138(Supplement 1). 3642–3642.
9.
Sharma, Manish, Babar Bashir, Erika Hamilton, et al.. (2021). 518MO Tolerability and preliminary clinical activity of SY-5609, a highly potent and selective oral CDK7 inhibitor, in patients with advanced solid tumors. Annals of Oncology. 32. S587–S588.
10.
Papadopoulos, Kyriakos P., Manish Sharma, Debra L. Richardson, et al.. (2020). Early evidence of dose-dependent pharmacodynamic activity following treatment with SY-5609, a highly selective and potent oral CDK7 inhibitor, in patients with advanced solid tumors. European Journal of Cancer. 138. S50–S50.
11.
Papadopoulos, Kyriakos P., Manish Sharma, Erika Hamilton, et al.. (2020). First-in-human phase I study of SY-5609, an oral, potent, and selective noncovalent CDK7 inhibitor, in adult patients with select advanced solid tumors.. Journal of Clinical Oncology. 38(15_suppl). TPS3662–TPS3662.
12.
Straus, David J., Monika Długosz‐Danecka, Árpád Illés, et al.. (2019). Brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma: Three-year update of the ECHELON-1 study.. Journal of Clinical Oncology. 37(15_suppl). 7532–7532.
13.
Gallamini, Andrea, David Straus, Monika Długosz‐Danecka, et al.. (2019). S820 FRONTLINE BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY FOR STAGE 3/4 CLASSICAL HODGKIN LYMPHOMA: 3‐YEAR UPDATE OF THE ECHELON‐1 STUDY. HemaSphere. 3(S1). 362–363.
14.
Chen, Robert W., Stephen M. Ansell, Andrea Gallamini, et al.. (2018). Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS).. Journal of Clinical Oncology. 36(15_suppl). 7539–7539.
15.
Evens, Andrew M., Joseph M. Connors, Anas Younes, et al.. (2018). Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study. Blood. 132(Supplement 1). 1618–1618.
16.
Crosswell, Howland E., Ann S. LaCasce, Nancy L. Bartlett, et al.. (2018). Brentuximab Vedotin with Chemotherapy in Adolescents and Young Adults (AYA) with Stage III or IV Hodgkin Lymphoma: A Subgroup Analysis from the Phase 3 Echelon-1 Study. Blood. 132(Supplement 1). 1647–1647.
17.
Connors, Joseph M., Anas Younes, Andrea Gallamini, et al.. (2018). Brentuximab Vedotin Plus Chemotherapy in Patients with Advanced-Stage Classical Hodgkin Lymphoma (cHL): Evaluation of Modified Progression-Free Survival (mPFS) and Traditional PFS in the Phase 3 ECHELON-1 Study. Blood. 132(Supplement 1). 2904–2904.
18.
Silverman, Jon, et al.. (2013). Pharmacotherapy Prevention and Management of Nutritional Deficiencies Post Roux-en-Y Gastric Bypass. Obesity Surgery. 23(7). 992–1000.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by A. E. Heufelder Breakdown of academic impact, for papers by Penko Shotekov Breakdown of academic impact, for papers by Erika Pigatto Breakdown of academic impact, for papers by Maria Stelmachowska‐Banaś Breakdown of academic impact, for papers by Sayaka Toki Breakdown of academic impact, for papers by Zoltán Szűcs Breakdown of academic impact, for papers by Jérôme Meunier Breakdown of academic impact, for papers by Eva Nóvoa Breakdown of academic impact, for papers by Javier Oesterheld Breakdown of academic impact, for papers by Eetu Heervä